LAMTOR5 and ovarian carcinoma: Additionally, ovarian cancer patients with high HBXIP expression had decreased OS compared with those with low HBXIP expression in either early-stage cases (Log-rank = 5.459, P = 0.019) or late-stage cases (Log-rank = 9.595, P = 0.002) (Fig. 3g–h).